No Increase in GBS Seen After COVID-19 Vaccination in Adults

Reporting rate of Guillain-Barré syndrome higher compared with other vaccinations, but rate within incidence range for general population

covid vaccine
Adobe Stock

MONDAY, Oct. 17, 2022 (HealthDay News) -- There is an increase in the reporting rate of Guillain-Barré syndrome (GBS) after COVID-19 vaccination, but the rate is within the incidence range for the general population, according to a study published online Sept. 22 in Vaccine.

Mustafa Jaffry, from Rutgers New Jersey Medical School in Newark, and colleagues compared the reporting rate of adult GBS after COVID-19 vaccination to the reporting rate after other vaccinations during the same time period and during control time periods.

The researchers observed a significantly higher reporting rate of GBS after COVID-19 vaccination than after influenza and other vaccinations (49.7, 0.19, and 0.16 per 10 million, respectively). The reporting rate for GBS was within the general population incidence range. A significant difference in the reporting rate of GBS after COVID-19 vaccination was seen between the risk period and control period using self-controlled and case-centered analyses. Within six weeks of COVID-19 vaccination, there were an estimated 0.7 to 1.7 per million excess reports of GBS. Associations for worse outcome were seen for female gender and age 18 to 44 years in a machine learning model. There was no association between the onset interval of GBS and prognosis.

"This study seeks to add to the body of knowledge surrounding the association between COVID-19 vaccination and GBS, so that health care providers may explain the risk/benefit ratio to patients to aid adherence to vaccination guidelines," the authors write.

Abstract/Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on October 17, 2022

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ